US Patent 11324762 Deuterated derivatives of psilocybin and uses thereof
Patent 11324762 was granted and assigned to Lennham Pharmaceuticals on May, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 9 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 2 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 17 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 22 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Inventor Names
Bradford Sippy0
Edits on 22 Apr, 2023
Golden AI
Infobox
Edits on 3 Apr, 2023
Golden AI
Infobox
Edits on 8 Mar, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 1 Mar, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 25 Sep, 2022
Golden AI
Infobox
Edits on 31 Aug, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 19 May, 2022
Golden AI
Edits made to:
Infobox (+12 properties)
Article (+239 characters)
US Patent 11324762 Deuterated derivatives of psilocybin and uses thereof
Article
Provided herein are pharmaceutical compositions comprising deuterated derivatives of psilocybin. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as mood or psychiatric disorders.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11324762
Date of patent
May 10, 2022
Patent application number
17406766
Date Filed
August 19, 2021
Patent primary examiner
CPC Code
Find more entities like US Patent 11324762 Deuterated derivatives of psilocybin and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.